Abstract. Human papillomavirus (HPV) has emerged as the predominant etiologic driver of oropharyngeal squamous cell carcinoma (OPSCC) in high-income countries, producing a clinically and molecularly distinct disease from the tobacco- and alcohol-associated carcinomas that historically defined the head and neck. HPV-associated OPSCC affects a comparatively younger, healthier population, favors the tonsil and base of tongue, and carries a markedly more favorable prognosis than HPV-negative disease. This review summarizes current evidence on the epidemiology, risk factors, diagnosis, staging, prognosis, and prevention of HPV-associated oropharyngeal cancer, and considers the role of the dental team in early detection and risk reduction.
Epidemiology
The incidence of oropharyngeal cancer has risen substantially over recent decades even as tobacco-related head and neck cancers have declined, a divergence attributable to HPV. In the United States, an estimated 66.3% of OPSCC cases are HPV-positive, and analyses of large national datasets have documented continued increases in oropharyngeal cancer incidence, with the sharpest rises among adults aged 65 years and older. The age-standardized incidence of HPV-associated OPSCC is consistently higher in men than in women. Notably, incidence of HPV-related OPSCC among younger adults has begun to decline in the vaccination era relative to the pre-vaccination period, an early population-level signal consistent with vaccine impact.
Etiology and Risk Factors
HPV16 accounts for the overwhelming majority of HPV-positive OPSCC, with HPV DNA identifiable in roughly two-thirds of oropharyngeal tumors. The virus establishes infection in the reticulated epithelium of the tonsillar crypts, where viral oncoproteins E6 and E7 inactivate the p53 and retinoblastoma (Rb) tumor-suppressor pathways, driving malignant transformation. Epidemiologic risk correlates include number of lifetime oral sexual partners, consistent with sexual transmission of oral HPV. Importantly, the HPV-positive patient population is frequently younger and often lacks the heavy tobacco and alcohol exposure characteristic of HPV-negative disease, although concurrent tobacco use adversely modifies prognosis.
Diagnosis and p16 Testing
Determination of HPV status is now standard in the workup of oropharyngeal carcinoma because it carries both prognostic and staging implications. Immunohistochemistry for p16, a surrogate marker of HPV-driven oncogenesis, is the most widely used clinical test owing to its accessibility and strong correlation with transcriptionally active infection, and it serves as the basis for HPV classification under current staging guidance. Recognizing the possibility of p16/HPV discordance is clinically relevant, as multi-cohort analyses have shown that discordant cases carry an intermediate prognosis, prompting recommendations for confirmatory HPV-specific testing in selected settings.
Staging and Prognosis
The prognostic distinction between HPV-positive and HPV-negative OPSCC is sufficiently large that the eighth edition of the AJCC/TNM staging system (TNM8) introduced a separate classification for p16-positive disease. HPV-positive tumors are more responsive to chemoradiotherapy and demonstrate substantially better outcomes, with reported five-year overall survival exceeding 90% in p16-positive cohorts. The prognostic effect of p16 status is strongest in tumors of the tonsil and base of tongue and diminishes in more distant subsites. This favorable biology has motivated ongoing investigation of treatment-de-escalation strategies intended to preserve survival while reducing long-term toxicity; however, the literature also cautions that uncritical application of TNM8 stage groupings should not by itself drive de-escalation outside of clinical trials.
Prevention and the Role of the Dental Team
Prophylactic HPV vaccination targeting high-risk genotypes, including HPV16, is the principal primary-prevention strategy, and vaccination has been associated with reduced odds of oral and oropharyngeal cancer in both sexes. Because dental professionals routinely examine the oropharynx, they are positioned to contribute to secondary prevention through systematic visual and palpation-based examination of the tonsillar region, base of tongue, and cervical lymph nodes, and to reinforce vaccination and tobacco- and alcohol-cessation counseling. Persistent unilateral throat symptoms, a non-healing lesion, or an asymptomatic neck mass warrant prompt referral. A patient-facing companion to this review is available in our guide to oral cancer, HPV, and screening.
Conclusion
HPV-associated oropharyngeal cancer represents a distinct and increasingly prevalent entity with a characteristic epidemiology, molecular pathogenesis, and comparatively favorable prognosis. Accurate HPV/p16 assessment is central to staging and prognostication, while vaccination offers a durable route to primary prevention. As clinicians who examine the oropharynx regularly, dental practitioners have a meaningful role in early detection, appropriate referral, and prevention counseling.
References
1. Centers for Disease Control and Prevention. HPV and Oropharyngeal Cancer. CDC, 2024.
2. American Cancer Society. Oral Cavity and Oropharyngeal Cancer: Causes, Risk Factors, and Prevention. 2024.
3. Lechner M, Liu J, Masterson L, Fenton TR. HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. Nat Rev Clin Oncol. 2022;19(5):306–327.
4. Mehanna H, Taberna M, von Buchwald C, et al. Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis. Lancet Oncol. 2023;24(3):239–251.
5. Katz J. HPV-vaccine and reduced odds ratio for oral and oropharyngeal cancer in both genders. J Oral Pathol Med. 2025.
This article is intended for general educational purposes and does not constitute individual medical or dental advice. For evaluation of any concerning oral or throat symptom, the team at Fridman Family Dental Care in Valencia, CA is here to help — contact us to schedule an examination.
